Boston Scientific Scimed, Inc.

Minnesota Mining and Manufacturing Company

North Dakota State University

3m Innovative Properties Company

University of Minnesota

Kangas, Steven L.

Ankrum, James

Cezo, James, D.

Steven L Kangas

Patrick L Coleman

Richard J Rolando

Yen-Lane Chen

Jerald K Rasmussen

Steven M Heilmann

Frank N Jones

Andrew D Bicek

Ramesh C Kumar

Timothy Paul Harrah

Daniel James Horn

Martin R Willard

Jeffrey S Lindquist

Derek C Sutermeister

Mark W Boden

Kent David Harrison

Thomas A Kotnour

Adel F Dimian

John R Ballard

Daozhang Wang

Der-Shyang Chen

Hongxia Zeng

Julie B Stahl

Bert J Exsted

Jeffrey W Reineke

Annamaria Szabolcs

Dean J Stych

Emil D Sprute

Cass Alexander Hanson

Peter G Edelman

Sandra Nagale

Jaydeep Yeshwant Kokate

Joel R Munsinger

David Raab

Daniel Keith Tomaschko

Ajay Gupta

Kasyap Venkata Seethamraju

Gary Pederson

Robert Squire

Robert H Menzies

Jonathan Zoll

Jan D Seppala

Derek Kenneth Larson

Joseph Connolly

Martin Phelan

Katherine Routh

David Shreeve

Charles W Graves

Deanna Cavallaro

Michele C Tessmer

Jennifer J Sahlin

Edward Kopesky

James D Cezo

Robert N Squire

Gary J Pederson

Joseph M Connolly

James Ankrum

Jan Seppala

Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided.

Biodegradable drug eluting microsphere for the treatment of solid tumors

Systems and methods for performing transcatheter coronary artery bypass grafting procedures are provided. The methods generally involve passing the graft from the aorta to the coronary artery through the pericardial space. The systems include poke-out wires, a coring device, and devices for forming anastomoses at the proximal and distal ends of a vascular graft.

Methods and devices for minimally invasive transcatheter coronary artery bypass grafting

The present disclosure relates generally to devices, systems, and methods for coil embolization, and, more particularly, to use and methods of forming coated coils. In an aspect, an embolic system may include a coil having a proximal end, a distal end, and a length therebetween slidingly disposed within a sheath. A coating may be disposed about the coil. A delivery filament may be configured to be slidingly disposed within the sheath proximal of the coil such that the coil can be ejected from the distal end of the sheath into the working lumen of a microcatheter. The coating may be configured to substantially fracture as the coil transitions from being substantially aligned with a longitudinal axis of the microcatheter to substantially misaligned with the longitudinal axis of the microcatheter upon being ejected from the microcatheter. The coating may be configured to plasticize after being ejected into an aqueous environment.

Devices, systems, and methods for a coated coil

Medical devices as wells as methods for making and using medical devices are disclosed. An example medical device may include a left atrial appendage device. The left atrial appendage device may include an expandable frame configured to shift between a first configuration and an expanded configuration. A fabric mesh may be disposed along at least a portion of the expandable frame. An anti-thrombogenic coating may be disposed along the fabric mesh.

Left atrial appendage closure device with anti-thrombogenic covering

In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Rapidly degrading embolic particles with therapeutic agent release

Medical devices and methods for forming the medical devices are disclosed in the present application. In one illustrative example an occlusion balloon comprises an outer balloon member, and an inner balloon member having an inner wall and an outer wall and extending through at least a portion of the outer balloon member. In at least some examples, when forces acting on the inner wall of the inner balloon member equal forces acting on the outer wall of the inner balloon member, the inner balloon member defines a lumen.

Occlusion device

Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.

Methods of treating tissue of a patient, e.g., tissue of an organ such that the bladder, are described. The methods may comprise inserting a medical device within the bladder; and injecting a composition to separate a first layer of tissue from a second layer of tissue. The composition may comprise at least one polysaccharide compound having a concentration ranging from approximately 0.05% to approximately 25% by weight, with respect to the total weight of the composition. The composition may at least partially separate the first layer of tissue from the second layer of tissue. At least one of the first layer of tissue or the second layer of tissue may be a detrusor muscle tissue.

Compositions and methods for treatment of tissue

A system and method for treating atherosclerotic plaque. The system includes a first catheter including an expandable balloon and a second catheter including a lumen in fluid communication with a distal hole. The method includes inserting the first catheter into a body lumen adjacent to a plaque formation, and deploying a balloon from the first catheter adjacent to the plaque formation. In addition, the method includes inserting the second catheter adjacent to the first catheter, and routing the distal end portion of second catheter along at least a portion of the deployed balloon of the first catheter. Further, the method includes routing at least a portion of the second catheter into a subintimal space adjacent to the atherosclerotic plaque. Furthermore, the method includes injecting a therapeutic agent into the subintimal space adjacent to the atherosclerotic plaque.

Systems and methods for treating atherosclerotic plaque

According to an aspect of the present invention, a medical device is provided which comprises a metallic substrate and polymeric region disposed over and in contact with the metallic substrate. The polymeric region comprises (a) a block copolymer that comprises (i) a hard polymer block that comprises a high Tg monomer and (ii) a soft polymer block that comprises a low Tg monomer, (b) an adhesion promoting copolymer that comprises (i) a first monomer that covalently or non-covalently bonds with the metallic substrate and (ii) a second monomer that is compatible with the low Tg monomer and/or the high Tg monomer and (c) a therapeutic agent. The polymeric region may further comprise an optional polymer that is used to tailor the release rate of the therapeutic agent.

Medical devices having coating with improved adhesion

The present invention provides a microporous material or a membrane in which the membrane includes an azlactone moiety which is blended with or grafted to a thermoplastic polymer to provide a porous material having an internal structure characterized by a multiplicity of spaced, randomly disposed, non-uniform shaped, equiaxed particles of the polyazlactone polymer/thermoplastic polymer blends or the azlactone-graft copolymer. Each of the adjacent particles throughout the material are separated from one another to provide said material with a network of interconnected micropores and each of the particles are connected to each other by a plurality of fibrils. In addition to unmodified azlactone membranes, membranes which have been modified by subsequent reaction of the azlactone moiety with a suitable nucleophile are also included within the scope of the present invention. Preferred nucleophiles capable of reacting with an azlactone membrane of this invention include biologically significant nucleophiles such as amines, thiols and alcohols as well as amino acids, nucleic acids and proteins.

Thermally induced phase separated azlactone membrane

Blocking is substantially reduced between individual sheets having a thermal adhesive coated thereon by including a release agent with the thermal adhesive. Preferred release agents are materials which have previously been used as low-adhesion backsize (LAB) coatings in pressure-sensitive adhesive applications.

Substrate and a color proofing article having release agent/adhesive

Growing community of inventors

Woodbury, MN, United States of America

Steven L Kangas